Trastuzumab (a monoclonal antibody), the first-line of treatment for HER2+ breast cancers[8–10], has been shown to be active as a single agent[11,12] as well as in combination with chemotherapy[9,10,13] for the treatment of advanced stage HER2+ breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.